TY - JOUR T1 - Health and Economic Consequences of Universal Paid Sick Leave Policies During the COVID-19 Pandemic JF - medRxiv DO - 10.1101/2022.01.13.21268270 SP - 2022.01.13.21268270 AU - David Naimark AU - Juan David Rios AU - Sharmistha Mishra AU - Beate Sander AU - Petros Pechlivanoglou Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/14/2022.01.13.21268270.abstract N2 - Importance Universal paid sick-leave (PSL) policies have been implemented in jurisdictions to mitigate the spread of SARS-CoV-2. However empirical data regarding health and economic consequences of PSL policies is scarce.Objective To estimate effects of a universal PSL policy in Ontario, Canada’s most populous province.Design An agent-based model (ABM) to simulate SARS-CoV-2 transmission informed by data from Statistics Canada, health administrative sources, and from the literature.Setting Ontario from January 1st to May 1st, 2021.Participants A synthetic population (1 million) with occupation and household characteristics representative of Ontario residents (14.5 million).Exposure A base case of existing employer-based PSL alone versus the addition of a 3-or 10-day universal PSL policy to facilitate testing and self-isolation among workers infected with SARS-CoV-2 themselves or because of infected household members.Main Outcome(s) and Measure(s) Number of SARS-CoV-2 infections and COVID-19 hospitalizations, worker productivity, lost wages, and presenteeism (going to a workplace while infected).Results If a 3- and 10-day universal PSL were implemented over the 4-month study period, then compared with the base-case, the PSL policies were estimated to reduce cumulative SARS-CoV-2 cases by 85,531 (95% credible interval, CrI -2,484; 195,318) and 215,302 (81,500; 413,742), COVID-19 hospital admissions by 1,307 (-201; 3,205) and 3,352 (1,223; 6,528), numbers of workers forgoing wages by 558 (-327;1,608) and 7,406 (6,764; 8,072), and numbers of workers engaged in presenteeism by 24,499 (216; 54,170) and 279,863 (262,696; 295,449). Hours of productivity loss were estimated to be 10,854,379 (10,212,304; 11,465,635) in the base case, 17,446,525 (15,934,321; 18,854,683) in the 3-day scenario, and 26,127,165 (20,047,239; 29,875,161) in the 10-day scenario. Lost wages were $5,256,316 ($4,077,280; $6,804,983) and $12,610,962 ($11,463,128; $13,724,664) lower in the 3 day and 10 day scenarios respectively, relative to the base case.Conclusions and Relevance Expanded access to PSL is estimated to reduce total numbers of COVID-19 cases, reduce presenteeism of workers with SARS-CoV-2 at workplaces, and mitigate wage loss experienced by workers.Competing interests The authors have no competing interests relevant to this article to disclose.Funding Supported by COVID-19 Rapid Research Funding (C-291-2431272-SANDER). This research was further supported, in part, by a Canada Research Chair in Economics of Infectious Diseases held by Beate Sander (CRC-950-232429). The study sponsor had no role in the design, collection, analysis, interpretation of the data, manuscript preparation or the decision to submit for publication.Author Contributions Conceptualization: PP, JDR, BS, DNData Curation: PP, JDR, BS, DNFormal Analysis: PP, JDR, DNMethodology: PP, JDR, BS, DNSupervision: PP, DN, BSValidation: PP, JDR, BS, DNFirst Draft: PP, JDR, BS, DNReview and EditPP, JDR, BS, DNQuestion What could be the health and economic consequence of more generous paid sick leave policies in the context of the COVID-19 pandemic?Findings More generous policies are estimated to reduce SARS-CoV-2 infections (and thus COVID-19 hospitalizations), lost wages and presence of individuals with infection at workplaces.Meaning More generous paid sick leave can be a valuable addition to other COVID-19 public health interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported by COVID-19 Rapid Research Funding (C-291-2431272-SANDER). This research was further supported, in part, by a Canada Research Chair in Economics of Infectious Diseases held by Beate Sander (CRC-950-232429). The study sponsor had no role in the design, collection, analysis, interpretation of the data, manuscript preparation or the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data used in the present study originate from pblished literature and publically available sources. references are provided in the main manuscript and in supplementary materialsI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the present study originate from pblished literature and publically available sources. ER -